<DOC>
	<DOCNO>NCT00842504</DOCNO>
	<brief_summary>The purpose study examine pharmacokinetics micafungin give every day schedule . The study determine every day micafungin provide drug exposure equivalent daily dose reduce administration cost improve patient convenience . Fifteen patient enrol study . Blood sample PK measurement obtain 48 hour follow single dose micafungin ( 3 mg/kg ) .</brief_summary>
	<brief_title>Alternate Day Micafungin : A PK Study Pediatric Patients</brief_title>
	<detailed_description>Disseminated fungal infection major cause morbidity mortality immunocompromised child . Many drug use fungal prophylaxis associate kidney liver toxicity . Also , breakthrough infection report use oral agent due poor oral absorption . An alternative approach use intravenous micafungin fungal prophylaxis . Micafungin distinct advantage due good safety profile , specifically term liver kidney toxicity . Currently , child receive micafungin give daily dose . This study examine pharmacokinetics micafungin give every day schedule . It examine whether every day micafungin provide drug exposure equivalent daily dose reduce administration cost improve patient convenience . Both animal adult human data support use approach . Fifteen patient enrol study give single dose micafungin ( 3 mg/kg ) . Blood sample draw pharmacokinetic measurement administration micafungin .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Hospitalized patient risk fungal infection require prophylaxis . Age ≤ 10 year exclude neonate Children must indwell venous access device Patients adequate organ function ( document within 2 week prior start micafungin ) : creatinine &lt; 2 time upper limit normal ; ALT , AST total bilirubin ≤ 3 time upper limit normal Patients &lt; 28 day old ( neonate ) &gt; 10 year age Patients history past evidence active fungal disease ( either radiological study biopsy proven ) treat presumed fungal infection . Patients history allergy micafungin echinocandin preparation , Caspofungin Anidulafungin . Patients receive micafungin echinocandin preparation previous two week . Patients receive antifungal prophylaxis Fluconazole time enrollment . Failure sign inform consent , inability undergo inform consent process . Not medically advisable obtain specimens necessary .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Anti-fungal</keyword>
	<keyword>Immunocompromised</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>